Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl G Nicholson

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 3, 2008
Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenzaAllan J Wailoo, Alexander J Sutton, Nicola J Cooper, et al.
The New England Journal of Medicine|October 10, 2008
Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1Iain Stephenson, Karl G Nicholson, Katja Hoschler, et al.
Chest|October 30, 2010
Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPDMona Bafadhel, Tristan W Clark, Carlene Reid, et al.
International Journal of Epidemiology|November 22, 2014
Cochrane columnCharles S Wiysonge, Folasade B Adeniyi, Nahoko Shindo, et al.
Vaccine|October 6, 2009
Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulationsKarl G Nicholson, Catherine I Thompson, Jaco M Klap, et al.
Lancet (London, England)|December 20, 2003
Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trialIain Stephenson, Karl G Nicholson, Reinhardt Glück, et al.
The Journal of Infection|August 10, 2022
Respiratory virus transmission using a novel viral challenge model: An observational cohort studyMarie-Jo Medina, Joshua Nazareth, Helen M Dillon, et al.
Journal of Virology|April 28, 2006
Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteersIain Stephenson, Maria C Zambon, Anna Rudin, et al.
Health Technology Assessment (Winchester, England)|May 31, 2014
Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-oldsKarl G Nicholson, Keith R Abrams, Sally Batham, et al.
The Lancet. Infectious Diseases|December 21, 2010
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trialKarl G Nicholson, Keith R Abrams, Sally Batham, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 3, 2008
Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenzaAllan J Wailoo, Alexander J Sutton, Nicola J Cooper, et al.
The New England Journal of Medicine|October 10, 2008
Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1Iain Stephenson, Karl G Nicholson, Katja Hoschler, et al.
Chest|October 30, 2010
Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPDMona Bafadhel, Tristan W Clark, Carlene Reid, et al.
International Journal of Epidemiology|November 22, 2014
Cochrane columnCharles S Wiysonge, Folasade B Adeniyi, Nahoko Shindo, et al.
Vaccine|October 6, 2009
Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulationsKarl G Nicholson, Catherine I Thompson, Jaco M Klap, et al.
Lancet (London, England)|December 20, 2003
Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trialIain Stephenson, Karl G Nicholson, Reinhardt Glück, et al.
The Journal of Infection|August 10, 2022
Respiratory virus transmission using a novel viral challenge model: An observational cohort studyMarie-Jo Medina, Joshua Nazareth, Helen M Dillon, et al.
Journal of Virology|April 28, 2006
Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteersIain Stephenson, Maria C Zambon, Anna Rudin, et al.
Health Technology Assessment (Winchester, England)|May 31, 2014
Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-oldsKarl G Nicholson, Keith R Abrams, Sally Batham, et al.
The Lancet. Infectious Diseases|December 21, 2010
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trialKarl G Nicholson, Keith R Abrams, Sally Batham, et al.
Pageof 5